58 related articles for article (PubMed ID: 18176767)
1. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
Bierbrier R; D'Aguanno K; Oliel S; Zeng Y; Esfahani K; Pehr K
J Cutan Med Surg; 2023 Nov; 27(6):614-620. PubMed ID: 37942582
[TBL] [Abstract][Full Text] [Related]
2. Bromide-Induced Acneiform Eruption.
Endo R; Tanaka R; Nomura T
Dermatitis; 2023; 34(4):276-277. PubMed ID: 36917540
[No Abstract] [Full Text] [Related]
3. Dose-Related Aripiprazole-Induced Acneiform Eruption.
Park HE; Kim YH; Lee JH
Ann Dermatol; 2023 May; 35(Suppl 1):S168-S169. PubMed ID: 37853901
[No Abstract] [Full Text] [Related]
4. Mechanism of action of adapalene for treating EGFR-TKI-induced skin disorder.
Mimura C; Nagano T; Miwa N; Matsumura K; Yamada J; Satoh H; Suraya R; Hazama D; Tamura D; Yamamoto M; Tachihara M; Nishimura Y; Kobayashi K
Thorac Cancer; 2024 Mar; 15(9):722-729. PubMed ID: 38379420
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers.
Espinosa ML; Abad C; Kurtzman Y; Abdulla FR
Front Oncol; 2021; 11():605941. PubMed ID: 34123780
[TBL] [Abstract][Full Text] [Related]
6. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).
Labadie JD; Hua X; Harrison TA; Banbury BL; Huyghe JR; Sun W; Shi Q; Yothers G; Alberts SR; Sinicrope FA; Goldberg RM; George TJ; Penney KL; Phipps AI; Cohen SA; Peters U; Chan AT; Newcomb PA
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):404-411. PubMed ID: 33203692
[TBL] [Abstract][Full Text] [Related]
7. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
8. Clinical response of acneiform eruptions caused by cetuximab to administration of oral tetracycline and topical ketoconazole.
Nakamura S; Hashimoto Y; Nishi K; Mizumoto T; Takahashi H; Iizuka H
J Dermatol Case Rep; 2014 Mar; 8(1):16-9. PubMed ID: 24748906
[TBL] [Abstract][Full Text] [Related]
9. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
Lacouture ME; Anadkat MJ; Bensadoun RJ; Bryce J; Chan A; Epstein JB; Eaby-Sandy B; Murphy BA;
Support Care Cancer; 2011 Aug; 19(8):1079-95. PubMed ID: 21630130
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with adapalene of cetuximab-induced acneiform eruptions.
Taguchi K; Fukunaga A; Okuno T; Nishigori C
J Dermatol; 2012 Sep; 39(9):792-4. PubMed ID: 22168666
[No Abstract] [Full Text] [Related]
11. Images in clinical medicine. Cetuximab-associated acneiform eruption.
Moss JE; Burtness B
N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
[No Abstract] [Full Text] [Related]
12. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
13. Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese SB; Neal JW; Kwong BY
Curr Treat Options Oncol; 2015 Oct; 16(10):50. PubMed ID: 26338208
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
[No Abstract] [Full Text] [Related]
15. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
